Business
Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
AURORA, Ontario, June 23 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced t...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, Ontario, June 23 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: HBP;\nOTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the\nOTCQX International Market under the ticker symbol HXBPF. Investors can find\nreal-time quotes, disclosure and financial information about the OTCQX\nInternational Market at www.otcqx.com.\n\n\n"Our OTCQX listing provides Helix with enhanced local access to the\nlargest capital market in the world," said John Docherty, president and chief\noperating officer of Helix. "Following our recently announced 20-F SEC\nregistration, our OTCQX listing is another important steppingstone towards our\nultimate goal of a listing on a major U.S. stock exchange such as The NASDAQ."\n\n\nU.S. investment bank, Merriman Curhan Ford, will serve as Helix's\nPrincipal American Liaison ("PAL") on the OTCQX and will be responsible for\nproviding guidance on the Company's continuing OTCQX-listing requirements and\narranging a comprehensive suite of U.S. capital market services.\n\n\n"Merriman is very pleased to sponsor Helix and to serve as their PAL,"\nsaid Stephen Nash, managing director and head of Merriman Curhan Ford's OTCQX\nAdvisory Group. "With our leadership in the advising, financing and trading\nof small capitalization health care companies, Merriman is uniquely positioned\nto help raise this exciting company's profile amongst U.S. investors."\n\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX and FSE under the symbol "HBP" and on the OTCQX International\nMarket under the symbol "HXBPF".\n\n\n\nAbout Merriman Curhan Ford\n\n\nMerriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused\non fast-growing companies and the institutions that invest in them. The\ncompany offers high-quality investment banking, equity research, institutional\nservices and corporate & venture services, and specializes in five growth\nindustry sectors: C...